Cargando…
Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)
INTRODUCTION: This Italian multicenter retrospective study evaluated safety and efficacy of the anti-TNF drug, adalimumab, in a cohort of patients affected by tuberculosis (TB), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV). Psoriasis is an autoimmune disease...
Autores principales: | Narcisi, Alessandra, Bernardini, Nicoletta, Orsini, Diego, D’Agostino, Magda, De Felice, Catia, Di Stefani, Alessandro, Carboni, Valentina, Costanzo, Antonio, Mastroianni, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394150/ https://www.ncbi.nlm.nih.gov/pubmed/32792888 http://dx.doi.org/10.5114/ada.2020.96910 |
Ejemplares similares
-
Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016) -
Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007) -
Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008) -
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016) -
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)